4lly: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{STRUCTURE_4lly| PDB=4lly | SCENE= }} | {{STRUCTURE_4lly| PDB=4lly | SCENE= }} | ||
===Crystal structure of Pertuzumab Clambda Fab with variable and constant domain redesigns (VRD2 and CRD2) at 1.6A=== | ===Crystal structure of Pertuzumab Clambda Fab with variable and constant domain redesigns (VRD2 and CRD2) at 1.6A=== | ||
{{ABSTRACT_PUBMED_24463572}} | |||
==About this Structure== | ==About this Structure== | ||
[[4lly]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLY OCA]. | [[4lly]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLY OCA]. | ||
==Reference== | |||
<ref group="xtra">PMID:024463572</ref><references group="xtra"/><references/> | |||
[[Category: Atwell, S.]] | [[Category: Atwell, S.]] | ||
[[Category: Chamberlain, A K.]] | [[Category: Chamberlain, A K.]] | ||
Revision as of 04:23, 13 February 2014
Crystal structure of Pertuzumab Clambda Fab with variable and constant domain redesigns (VRD2 and CRD2) at 1.6A
Template:ABSTRACT PUBMED 24463572
About this Structure
4lly is a 4 chain structure. Full crystallographic information is available from OCA.
Reference
- Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, Hansen-Estruch C, Chamberlain AK, Truhlar SM, Conner EM, Atwell S, Kuhlman B, Demarest SJ. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol. 2014 Feb;32(2):191-8. doi: 10.1038/nbt.2797. Epub 2014 Jan 26. PMID:24463572 doi:https://dx.doi.org/10.1038/nbt.2797
